General
Preferred name
TOBRAMYCIN
Synonyms
Nebramycin ()
Tobrasix ()
Nebcine ()
Deoxykanamycin B sulfate ()
Nebramycin Factor 6 sulfate ()
Dartobcin ()
Tobraneg ()
NSC 180514 ()
Nebramycin Factor 6 ()
Deoxykanamycin B ()
NSC 180514,Deoxykanamycin B, Nebramycin Factor 6 ()
TOBRAMYCIN SULFATE ()
Aktob ()
Nebris ()
Tobramycine ()
Bethkis ()
Tobravisc ()
Tobramycin component of tobrasone ()
Tobramicina ()
Tobrex ()
Bramitob ()
Kitabis pak ()
Vantobra (previously tobramycin pari) ()
Tobramycin component of tobradex ()
Nebicin ()
Nebcin ()
Tymbrineb ()
Vantobra ()
Tobi ()
Tobramycin component of tobradex st ()
Nebramycin vi ()
47663 ()
Tobi podhaler ()
Tobralex ()
Tobramycin component of zylet ()
NSC-180514 ()
Tobramycin sulphate ()
Tobra ()
Tobramycin sulfate (2:5) ()
Gernebcin ()
Tobramycin Sulfate (Pharmacy Bulk) ()
Obracin ()
Nebicina ()
Tobradistin ()
Tobramycin (sulfate) ()
P&D ID
PD001728
CAS
32986-56-4
49842-07-1
11098-01-4
Tags
available
drug
natural product
biased GPCR ligand
Approved by
FDA
EMA
First approval
1975
Drug indication
osteomyelitis
Bacterial conjunctivitis
Bacterial infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tobramycin is an aminoglycoside antibacterial that was originally isolated from Streptomyces tenebrarius. It is particularly effective against Gram-negative infections (especially Pseudomonas spp. infections). Like other aminoglycosides it is ototoxic and nephrotoxic. (GtoPdb)
PRICE 29
DESCRIPTION Potent MCT1 inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Tobramycin (NSC-180514) is an aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. (TargetMol Bioactive Compound Library)
DESCRIPTION Tobramycin Sulfate (Dartobcin) is an antibacterial nanomedicine, useful in pediatric bacterial pneumonia research. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
24
BiasDB
Tobramycin
Cayman Chemical Bioactives
14596
41453
ChEMBL Approved Drugs
CHEMBL1747
CHEMBL3989564
ChEMBL Drugs
CHEMBL1747
CHEMBL3989564
Concise Guide to Pharmacology 2023/24
10930
Drug Repurposing Hub
DrugBank
DB00684
DrugBank Approved Drugs
DB00684
DrugCentral
2684
DrugCentral Approved Drugs
2684
DrugMAP
DMUI0CH
DrugMAP Approved Drugs
DMUI0CH
Guide to Pharmacology
10930
MedChem Express Bioactive Compound Library
HY-B0441
NCATS Inxight Approved Drugs
VZ8RRZ51VK
NPC Screening Collection
Other bioactive compounds
Pandemic Response Box
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Tobramycin(free-base)
tobramycin-sulfate
TargetMol Bioactive Compound Library
T1255
T1255L
The Spectrum Collection
Tocris Bioactive Compound Library
5390
External IDs
81
Properties
(calculated by RDKit )
Molecular Weight
467.26
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
10
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
0
cLogP
-6.3
TPSA
268.17
Fraction CSP3
1.0
Chiral centers
14.0
Largest ring
6.0
QED
0.17
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Bacterial
antibiotic
30S ribosome
Antibiotics,Antineoplastic and Immunosuppressive Antibiotics
Antibiotics,Bacterial
Primary Target
Antibiotics
MOA
ribosome inhibitor
bacterial 30S ribosomal subunit inhibitor
Indication
bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections
Pathway
Microbiology/virology
Anti-infection
Source data